NCT07030504View on ClinicalTrials.gov

To Evaluate the Safety, Tolerability and Pharmacokinetic of SAL0133 Tablets in Chinese Adult Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Pharmacokinetics
Interventions
DRUG

SAL0133

once daily single dose or seven days multiple dose of SAL0133 tables

DRUG

SAL0133 placebo

once daily single dose or seven days multiple dose of SAL0133 placebo

Trial Locations (1)

Unknown

Shenzhen People's Hospital, Shenzhen

All Listed Sponsors
lead

Shenzhen Salubris Pharmaceuticals Co., Ltd.

INDUSTRY